Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential efgartigimod followed by ofatumumab for generalized myasthenia gravis
ChiCTR2400084937Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa and ofatumumab in myasthenia gravis (MG), sponsored by Peking University People's Hospital. Primary endpoints: Change in MGFA-QMG score from baseline at Week 24, Change in MG-ADL score from baseline at Week 24 and 1 more. Started May 2024; status: completed.
02
Drugs
efgartigimod alfaofatumumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2400084937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084937.